[
    {
        "pregunta": "1. What are the recommendations for patients with RMD regarding the use of combined estrogen-progestin contraceptives?",
        "respuesta": "The recommendations for patients with rheumatic and musculoskeletal diseases (RMD) regarding the use of combined estrogen-progestin contraceptives are as follows:\n\n- For patients with positive antiphospholipid antibodies (aPL), it is strongly recommended not to use combined estrogen-progestin contraceptives. Instead, the use of an intrauterine device (IUD) or progestin-only pill is recommended. \n\nBeyond this specific recommendation for patients with positive aPL, there is no further information provided about the general use of combined estrogen-progestin contraceptives in patients with RMD from the provided data.",
        "contexto": [
            "College of Rheumatology is an independent, professional, medical and scientific society that does not guarantee, warrant, or endorse any commercial product or service. INTRODUCTION The management of reproductive health issues in patients with rheumatic and musculoskeletal diseases (RMD) differs from that in healthy persons. As a result, rheumatologists and other clinicians caring for these patients must often discuss with and counsel their patients about contraception, pregnancy and lactation",
            "<p>|Topic|Recommendation|Strength|\n|---|---|---|\n|Contraception|All RMD|GPS|\n| |Contraception/pregnancy discussion early and regularly; choose contraception based on safety, efficacy, and patient preference| |\n| |Use barrier methods if unable to use other methods|GPS|\n| |Use emergency contraception if necessary [6]|Strong|\n| |Women receiving immunosuppressive medications: Use IUD if desired [7]|Strong|\n| |Women at risk for osteoporosis: Avoid DMPA [10]|Conditional|",
            "compatibility of many rheumatology medications both with lactation and with paternal use. The rheumatologist's familiarity with drug safety during these periods is important to maintain disease control and minimize mother and infant risk. Fertility and postmenopausal issues are not uncommon in RMD patients. Recommendations regarding ART reflect a growing demand among patients with RMD for fertility therapies. Oocyte freezing is now widely available The strength of evidence on reproductive",
            "| |Avoid transdermal estrogen-progestin patch [2B]|Conditional|\n| |SLE with negative aPL and moderate-to-high disease activity: Use progestin-only contraceptives or IUD [2C]|Strong|\n|Positive aPL|Do not use combined estrogen-progestin contraceptives [3]; use IUD or progestin-only pill [4]|Strong|\n|Assisted reproductive technology|All RMD|GPS|\n| |Stable disease and negative aPL: Proceed with assisted reproductive technology: IVF if pregnancy-compatible medications [24]|Strong|",
            "use by men and women or during pregnancy and lactation, but uncontrolled systemic inflammatory disease is itself associated with poor pregnancy outcomes Given the primary goal of providing recommendations for care of all adult RMD patients throughout the reproductive lifespan, the scope of this guideline is broad. There has been little attention to aspects of reproductive health care other than pregnancy in patients with RMD, and the American College of Rheumatology (ACR) recognizes the"
        ]
    },
    {
        "pregunta": "2. What is the preferred approach for patients at risk for osteoporosis in terms of contraceptive options?",
        "respuesta": "The preferred approach for patients at risk for osteoporosis in terms of contraceptive options is to avoid the use of depot medroxyprogesterone acetate (DMPA). Instead, alternative highly effective or effective contraceptive methods should be considered, depending on the patient's preferences and any contraindications. It is important to choose contraception based on safety, efficacy, and patient preference.",
        "contexto": [
            "risk, we strongly recommend continuing OP therapy (PICO 12.1-12.6).  Recommendations for initial treatment (Table 2 3 For adults ≥40 years with very high fracture risk, we conditionally recommend PTH/PTHrP over anti-resorptives (BP or DEN) (PICO 1.13c, 1.14c, 1.15c, 1.18c, 1.19c, 1.20c). Compared to alendronate, teriparatide increased lumbar and hip BMD and decreased vertebral but not nonvertebral fractures at 36 months in GIOP For adults ≥40 years with high or very high fracture risk, we",
            "initial therapy for those at very high risk for fracture based on BMD and vertebral fracture prevention superiority compared to anti-resorptives in patients with very high risk postmenopausal OP. Of note, abaloparatide and ROM are not approved in GIOP, and we recognize it may be difficult to access these medications for GIOP. The panel specifically noted that the potential harms of RAL (venous thromboembolism [VTE] and fatal stroke) and ROM (major myocardial infarction, stroke, and death) would",
            "<p>|Topic|Recommendation|Strength|\n|---|---|---|\n|Contraception|All RMD|GPS|\n| |Contraception/pregnancy discussion early and regularly; choose contraception based on safety, efficacy, and patient preference| |\n| |Use barrier methods if unable to use other methods|GPS|\n| |Use emergency contraception if necessary [6]|Strong|\n| |Women receiving immunosuppressive medications: Use IUD if desired [7]|Strong|\n| |Women at risk for osteoporosis: Avoid DMPA [10]|Conditional|",
            "Notably, most evidence reviewed in this guideline is downgraded for indirectness because 1) identified studies in GIOP rely on a surrogate fracture risk marker, bone mineral density (BMD), because they were not powered for fracture outcomes and 2) available fracture data were exclusively or predominantly from general osteoporosis (OP) studies. Recommendations for fracture risk assessment (Figure 1 Key recommendations For all adults (≥18 years old) initiating or continuing GC therapy ≥2.5 mg/day",
            "| |Women at risk for osteoporosis: Avoid DMPA [10]|Conditional|\n| |Women receiving MMF: Use IUD or 2 other methods together [11]|Conditional|\n| |RMD without SLE or aPL: Use highly effective or effective methods† [1]|Strong|\n| |Highly effective methods preferred to effective methods [1A]|Conditional|\n|SLE|SLE with negative aPL and low/stable disease activity: Use highly effective or effective methods† [2]|Strong|\n| |Highly effective methods preferred to effective methods [2A]|Conditional|"
        ]
    },
    {
        "pregunta": "3. How should stress-dose glucocorticoids be administered during vaginal delivery according to the guideline?",
        "respuesta": "The guidelines conditionally recommend against the routine administration of stress-dose glucocorticoids at the time of vaginal delivery. Therefore, stress-dose glucocorticoids should not be administered during vaginal delivery according to the guideline provided.",
        "contexto": [
            "administration of stress-dose glucocorticoids at the time of vaginal delivery, but conditionally do recommend such treatment for surgical (cesarean) delivery. We conditionally recommend continuing tumor necrosis factor inhibitor therapy with infliximab, etanercept, adalimumab, or golimumab prior to and during pregnancy Placental transfer and fetal exposure for most biologic therapies vary with gestational stage. The majority of RMD biologic therapies contain an Fc IgG1 construct that does not",
            "of prednisone or nonfluorinated equivalent) during pregnancy if clinically indicated. We strongly recommend tapering higher doses of nonfluorinated glucocorticoids to <20 mg daily of prednisone, adding a pregnancy-compatible glucocorticoid-sparing agent if necessary. Although there are only minimal data regarding prolonged treatment with low-dose glucocorticoids during pregnancy, we conditionally recommend against routine administration of stress-dose glucocorticoids at the time of vaginal",
            "NSAIDs over cyclooxygenase 2-specific inhibitors in the first 2 trimesters, due to lack of data on cyclooxygenase 2-specific inhibitors. Nonfluorinated glucocorticoids should be used when needed, but substitution of steroid-sparing pregnancy-compatible immunosuppressive therapy is desirable when high-dose or prolonged use is required. We conditionally recommend continuing low-dose glucocorticoid treatment (≤10 mg daily of prednisone or nonfluorinated equivalent) during pregnancy if clinically",
            "shown on echocardiography, we conditionally recommend treatment with oral dexamethasone 4 mg daily. If CHB (without other cardiac inflammation) is present, we conditionally recommend against treating with dexamethasone. Fluorinated glucocorticoids, such as dexamethasone and betamethasone, cross the placenta; low-to-moderate-dose nonfluorinated glucocorticoids, such as prednisone and prednisolone, are largely metabolized before they reach the fetus. Whether dexamethasone given for fetal first-or",
            "|Continue regular low-dose prednisone [201]|Conditional| |\n|Taper high-dose prednisone with addition of pregnancy-compatible drug if needed|Strong| |\n|Stress-dose steroid at delivery: do not treat for vaginal delivery, do treat for cesarean delivery|Conditional| |\n|Breastfeeding|Encourage breastfeeding and maintain disease control with compatible medications if possible|GPS|\n|Compatible medications:|HCQ, infliximab, etanercept, adalimumab, golimumab, certolizumab, rituximab|Strong|"
        ]
    },
    {
        "pregunta": "4. What is the recommended approach for continuing tumor necrosis factor inhibitor therapy during pregnancy?",
        "respuesta": "The guidelines conditionally recommend continuing tumor necrosis factor (TNF) inhibitor therapy with agents such as infliximab, etanercept, adalimumab, or golimumab prior to and during pregnancy. Placental transfer and fetal exposure for most biologic therapies vary with gestational stage. Thus, according to the provided information, these TNF inhibitors can be continued during pregnancy under conditional recommendations.",
        "contexto": [
            "administration of stress-dose glucocorticoids at the time of vaginal delivery, but conditionally do recommend such treatment for surgical (cesarean) delivery. We conditionally recommend continuing tumor necrosis factor inhibitor therapy with infliximab, etanercept, adalimumab, or golimumab prior to and during pregnancy Placental transfer and fetal exposure for most biologic therapies vary with gestational stage. The majority of RMD biologic therapies contain an Fc IgG1 construct that does not",
            "periconception period but should be discontinued during pregnancy (i.e. at the time of the first positive pregnancy test result). We conditionally recommend continuing treatment with anakinra, belimumab, abatacept, tocilizumab, secukinumab, and ustekinumab while a woman is trying to conceive, but discontinuing once she is found to be pregnant. If disease cannot be controlled with medications considered compatible with pregnancy, the physician and patient should discuss and weigh the possible",
            "|Continue certolizumab [156]|Strong| |\n|Continue infliximab, etanercept, adalimumab, golimumab [144, 147, 150, 153]|Conditional| |\n|Stop when pregnancy confirmed: rituximab, belimumab, anakinra, abatacept, tocilizumab, secukinumab, ustekinumab [164, 169, 160, 173, 177, 181, 185]|Conditional| |\n|Use rituximab for organ-or life-threatening disease during pregnancy [165]|Conditional| |\n|No recommendations for tofacitinib, baricitinib, apremilast due to lack of data [189, 193, 197]| | |",
            "NSAIDs over cyclooxygenase 2-specific inhibitors in the first 2 trimesters, due to lack of data on cyclooxygenase 2-specific inhibitors. Nonfluorinated glucocorticoids should be used when needed, but substitution of steroid-sparing pregnancy-compatible immunosuppressive therapy is desirable when high-dose or prolonged use is required. We conditionally recommend continuing low-dose glucocorticoid treatment (≤10 mg daily of prednisone or nonfluorinated equivalent) during pregnancy if clinically",
            "of RMD biologic therapies contain an Fc IgG1 construct that does not cross into the fetal circulation in significant concentrations until the second trimester There are limited data on the compatibility of other biologics with pregnancy. Given that these agents likely do not cross the placenta until the second trimester, the panel conditionally recommends that non-TNF inhibitor IgG-based molecules are compatible in the periconception period but should be discontinued during pregnancy (i.e. at"
        ]
    },
    {
        "pregunta": "5. How do biologic therapies vary in terms of placental transfer and fetal exposure during pregnancy?",
        "respuesta": "Biologic therapies, specifically those containing an Fc IgG1 construct, do not cross into the fetal circulation in significant concentrations until the second trimester of pregnancy. Therefore, the placental transfer and fetal exposure of these biologic therapies vary with the gestational stage. The guidelines conditionally recommend continuing tumor necrosis factor (TNF) inhibitor therapy with agents such as infliximab, etanercept, adalimumab, or golimumab prior to and during pregnancy, as their placental transfer is limited until later stages of gestation. However, it is recommended that other non-TNF inhibitor IgG-based molecules should be discontinued during pregnancy, despite being compatible in the periconception period. There is no available evidence regarding the use or safety of newer small-molecule agents, such as tofacitinib, baricitinib, and apremilast, during pregnancy, but small molecules are likely to pass through the placenta.",
        "contexto": [
            "administration of stress-dose glucocorticoids at the time of vaginal delivery, but conditionally do recommend such treatment for surgical (cesarean) delivery. We conditionally recommend continuing tumor necrosis factor inhibitor therapy with infliximab, etanercept, adalimumab, or golimumab prior to and during pregnancy Placental transfer and fetal exposure for most biologic therapies vary with gestational stage. The majority of RMD biologic therapies contain an Fc IgG1 construct that does not",
            "of RMD biologic therapies contain an Fc IgG1 construct that does not cross into the fetal circulation in significant concentrations until the second trimester There are limited data on the compatibility of other biologics with pregnancy. Given that these agents likely do not cross the placenta until the second trimester, the panel conditionally recommends that non-TNF inhibitor IgG-based molecules are compatible in the periconception period but should be discontinued during pregnancy (i.e. at",
            "is whether his medication is present in seminal fluid and can transfer through vaginal mucosa, cross the placenta, and be teratogenic. In fact, post-conception exposure of the embryo or fetus is likely minimal,  as seminal concentrations of medications and volumes transferred are small In the absence of adequate data regarding paternal exposure for most medications used for RMD, we developed recommendation statements when 1) at least some data on paternal exposure were available, 2) accumulated",
            "half of pregnancy puts the fetus at high risk of having minimal B cells at delivery There is no available evidence regarding use or safety of the new small-molecule agents, tofacitinib, baricitinib, and apremilast, during pregnancy. The Voting Panel elected not to offer recommendations regarding these drugs. It should be noted, however, that small molecules are likely to pass through the placenta. Medication use during breastfeeding. The benefits of breastfeeding are numerous Infant serum",
            "immunization, and for this reason, the AAP recommends delaying rotavirus vaccination for 12 months after any in utero exposure to biologic DMARDs (except for certolizumab, which does not cross the placenta) The literature review identified no data on the effect of in utero rituximab exposure on later vaccine responses. Rituximab is a chimeric IgG1 molecule that can cross the placenta, and it has been associated with low or absent B lymphocyte levels in newborns who were exposed during the"
        ]
    },
    {
        "pregunta": "6. What is the panel's recommendation regarding the use of non-TNF inhibitor IgG-based molecules during the periconception period and pregnancy?",
        "respuesta": "The panel conditionally recommends that non-TNF inhibitor IgG-based molecules are compatible for use during the periconception period but should be discontinued once a woman is found to be pregnant, i.e., at the time of the first positive pregnancy test result. This recommendation is due to the limited placental transfer of these agents until the second trimester, after which they should not be used during the remainder of the pregnancy.",
        "contexto": [
            "of RMD biologic therapies contain an Fc IgG1 construct that does not cross into the fetal circulation in significant concentrations until the second trimester There are limited data on the compatibility of other biologics with pregnancy. Given that these agents likely do not cross the placenta until the second trimester, the panel conditionally recommends that non-TNF inhibitor IgG-based molecules are compatible in the periconception period but should be discontinued during pregnancy (i.e. at",
            "half of pregnancy puts the fetus at high risk of having minimal B cells at delivery There is no available evidence regarding use or safety of the new small-molecule agents, tofacitinib, baricitinib, and apremilast, during pregnancy. The Voting Panel elected not to offer recommendations regarding these drugs. It should be noted, however, that small molecules are likely to pass through the placenta. Medication use during breastfeeding. The benefits of breastfeeding are numerous Infant serum",
            "periconception period but should be discontinued during pregnancy (i.e. at the time of the first positive pregnancy test result). We conditionally recommend continuing treatment with anakinra, belimumab, abatacept, tocilizumab, secukinumab, and ustekinumab while a woman is trying to conceive, but discontinuing once she is found to be pregnant. If disease cannot be controlled with medications considered compatible with pregnancy, the physician and patient should discuss and weigh the possible",
            "administration of stress-dose glucocorticoids at the time of vaginal delivery, but conditionally do recommend such treatment for surgical (cesarean) delivery. We conditionally recommend continuing tumor necrosis factor inhibitor therapy with infliximab, etanercept, adalimumab, or golimumab prior to and during pregnancy Placental transfer and fetal exposure for most biologic therapies vary with gestational stage. The majority of RMD biologic therapies contain an Fc IgG1 construct that does not",
            "and pamidronate were suggested as alternatives for the treatment of patients with active disease and contraindications to TNFi, while the current recommendations suggest use of secukinumab or ixekizumab in most of these cases (except patients with high risk of infections). In cases of failure of TNFi, the 2015 guidelines included a conditional recommendation for a trial of a second TNFi and against use of a non-TNFi biologic, whereas the current guidelines differentiate treatment"
        ]
    },
    {
        "pregunta": "7. How should treatment with rituximab be managed in women trying to conceive and during pregnancy?",
        "respuesta": "The panel conditionally recommends continuing treatment with rituximab while a woman is trying to conceive. If severe life- or organ-threatening maternal disease warrants, rituximab may also be continued during pregnancy. However, it is important to note that dosing in the second half of pregnancy puts the fetus at high risk of having minimal B cells. Therefore, the decision to continue rituximab during pregnancy should involve a discussion between the physician and patient to weigh the possible risks of the medication versus the risks of uncontrolled disease during pregnancy.",
        "contexto": [
            "pregnancy, the physician and patient should discuss and weigh the possible risks from these medications versus the risks of uncontrolled disease during pregnancy. We conditionally recommend continuing treatment with rituximab while a woman is trying to conceive, and we conditionally recommend continuing rituximab during pregnancy if severe life-or organ-threatening maternal disease so warrants. Dosing in the second half of pregnancy puts the fetus at high risk of having minimal B cells at",
            "periconception period but should be discontinued during pregnancy (i.e. at the time of the first positive pregnancy test result). We conditionally recommend continuing treatment with anakinra, belimumab, abatacept, tocilizumab, secukinumab, and ustekinumab while a woman is trying to conceive, but discontinuing once she is found to be pregnant. If disease cannot be controlled with medications considered compatible with pregnancy, the physician and patient should discuss and weigh the possible",
            "treatment with rituximab over switching to cyclophosphamide for remission re-induction. Re-induction of remission with rituximab is favored over cyclophosphamide treatment to minimize toxicity. However, the duration of remission prior to the onset of relapse should be examined. Cyclophosphamide should be considered if a severe relapse occurred quickly after rituximab treatment, or if cardiac involvement is present (see ungraded position statement and recommendation on this topic).",
            "regarding infant rotavirus vaccination after in utero exposure to either TNFi or rituximab should be discussed with the pregnant RMD patient prior to delivery. Specifically, the pregnant patient should be educated as to the fact that medications that cross the placenta may affect vaccination schedules for their infants. A copy of the current vaccine guideline summary ( https:// www.rheumatology.org/Portals/0/Files/Vaccinations-Guidance- Whether to give multiple vaccinations to patients with RMD",
            "|Continue certolizumab [156]|Strong| |\n|Continue infliximab, etanercept, adalimumab, golimumab [144, 147, 150, 153]|Conditional| |\n|Stop when pregnancy confirmed: rituximab, belimumab, anakinra, abatacept, tocilizumab, secukinumab, ustekinumab [164, 169, 160, 173, 177, 181, 185]|Conditional| |\n|Use rituximab for organ-or life-threatening disease during pregnancy [165]|Conditional| |\n|No recommendations for tofacitinib, baricitinib, apremilast due to lack of data [189, 193, 197]| | |"
        ]
    },
    {
        "pregunta": "8. What is the guideline's stance on the use of small-molecule agents like tofacitinib, baricitinib, and apremilast during pregnancy?",
        "respuesta": "The guidelines do not provide specific recommendations regarding the use of small-molecule agents such as tofacitinib, baricitinib, and apremilast during pregnancy due to a lack of available data. It is noted that small molecules are likely to pass through the placenta, but the voting panel elected not to offer recommendations for these drugs.",
        "contexto": [
            "half of pregnancy puts the fetus at high risk of having minimal B cells at delivery There is no available evidence regarding use or safety of the new small-molecule agents, tofacitinib, baricitinib, and apremilast, during pregnancy. The Voting Panel elected not to offer recommendations regarding these drugs. It should be noted, however, that small molecules are likely to pass through the placenta. Medication use during breastfeeding. The benefits of breastfeeding are numerous Infant serum",
            "|Continue certolizumab [156]|Strong| |\n|Continue infliximab, etanercept, adalimumab, golimumab [144, 147, 150, 153]|Conditional| |\n|Stop when pregnancy confirmed: rituximab, belimumab, anakinra, abatacept, tocilizumab, secukinumab, ustekinumab [164, 169, 160, 173, 177, 181, 185]|Conditional| |\n|Use rituximab for organ-or life-threatening disease during pregnancy [165]|Conditional| |\n|No recommendations for tofacitinib, baricitinib, apremilast due to lack of data [189, 193, 197]| | |",
            "| Anakinra, belimumab, abatacept, tocilizumab, secukinumab, ustekinumab | + (Discontinue at conception)                                      | + (Discontinue during pregnancy)                                | Expect minimal transfer due to large molecular size, but no available data |",
            "| Thalidomide (discontinue 4 weeks prior to attempted conception) | Abatacept, Apremilast, Baricitinib, Belimumab, Secukinumab, Tocilizumab, Tofacitinib, Ustekinumab |</p>",
            "|---|---|\n|Conditional recommendation based on low-quality evidence; may consider tofacitinib if the patient prefers an oral therapy.|Conditional recommendation based on low-quality evidence; may consider tofacitinib if the patient prefers an oral therapy.|\n|13. Add apremilast to current OSM therapy over switching to apremilast (PICO 22b)|Low (83, 84, 108)|"
        ]
    },
    {
        "pregunta": "9. What are the recommendations for breastfeeding while on RMD medications such as HCQ, colchicine, and TNF inhibitors?",
        "respuesta": "The recommendations for breastfeeding while taking medications for rheumatic and musculoskeletal diseases (RMD) are as follows:\n\n- **Hydroxychloroquine (HCQ):** HCQ is strongly recommended as compatible with breastfeeding.\n\n- **Colchicine:** Colchicine is also strongly recommended as compatible with breastfeeding.\n\n- **Tumor Necrosis Factor (TNF) Inhibitors:** All TNF inhibitors are strongly recommended as compatible with breastfeeding.\n\nThese recommendations indicate that HCQ, colchicine, and TNF inhibitors can be used safely during breastfeeding, as they are considered compatible with lactation.",
        "contexto": [
            "breastfeeding. The benefits of breastfeeding are numerous Infant serum levels of drugs ingested by the mother depend on multiple variables and are a function of drug concentration in breast milk, quantity of breast milk ingested, and drug absorption through the infant's gastrointestinal tract. Premature infants Fortunately, many RMD medications may be initiated or continued during lactation. We strongly recommend treatment with HCQ, colchicine, sulfasalazine, rituximab, and all TNF inhibitors",
            "with HCQ, colchicine, sulfasalazine, rituximab, and all TNF inhibitors as compatible with breastfeeding We also recommend prednisone <20 mg daily (or equivalent nonfluorinated glucocorticoid) as compatible with breastfeeding, but strongly recommend that with doses of prednisone ≥20 mg a day (or equivalent), women delay breastfeeding or discard breast milk accumulated in the 4 hours following glucocorticoid administration. We conditionally recommend treatment with azathioprine/6-mercaptopurine,",
            "We conditionally recommend treatment with azathioprine/6-mercaptopurine, calcineurin inhibitors, NSAIDs and the non-TNF inhibitor biologic agents (anakinra, rituximab, belimumab, abatacept, tocilizumab, secukinumab, and ustekinumab) as compatible with breastfeeding We strongly recommend against use of CYC, leflunomide, MMF, and thalidomide while breastfeeding. We conditionally recommend against use of MTX while breastfeeding. Despite minimal passage of MTX into breast milk, especially with",
            "referral to a maternal-fetal medicine specialist, pregnancy medication specialist, or genetics counselor as standard good practice. We strongly recommend HCQ, azathioprine/6mercaptopurine, colchicine, and sulfasalazine, medications commonly used for RMD, as compatible for use throughout pregnancy We conditionally recommend calcineurin inhibitors (tacrolimus and cyclosporine) and NSAIDs as compatible for use during pregnancy We conditionally recommend discontinuation of NSAIDs pre-conception if",
            "Despite minimal passage of MTX into breast milk, especially with once-weekly dosing, this medication may accumulate in neonatal tissues DISCUSSION Patients' reproductive health concerns are relevant for all practicing rheumatologists. Issues regarding contraception, fertility, pregnancy, lactation, and the offspring's health affect almost every patient across all RMD diagnoses. The importance of this area is highlighted by recent publications that have addressed key elements of reproductive"
        ]
    },
    {
        "pregunta": "10. How should breastfeeding be managed for women taking prednisone at different dose levels?",
        "respuesta": "The recommendations for managing breastfeeding in women taking prednisone are as follows:\n\n- **Prednisone <20 mg daily:** This dose is considered compatible with breastfeeding. Women can continue to breastfeed while taking this dose of prednisone or an equivalent nonfluorinated glucocorticoid.\n\n- **Prednisone ≥20 mg daily:** It is strongly recommended that women delay breastfeeding or discard breast milk accumulated in the 4 hours following glucocorticoid administration. This precaution is advised to minimize the infant's exposure to higher doses of glucocorticoids through breast milk.\n\nThese recommendations encourage breastfeeding while maintaining disease control with compatible medications whenever possible.",
        "contexto": [
            "with HCQ, colchicine, sulfasalazine, rituximab, and all TNF inhibitors as compatible with breastfeeding We also recommend prednisone <20 mg daily (or equivalent nonfluorinated glucocorticoid) as compatible with breastfeeding, but strongly recommend that with doses of prednisone ≥20 mg a day (or equivalent), women delay breastfeeding or discard breast milk accumulated in the 4 hours following glucocorticoid administration. We conditionally recommend treatment with azathioprine/6-mercaptopurine,",
            "|Continue regular low-dose prednisone [201]|Conditional| |\n|Taper high-dose prednisone with addition of pregnancy-compatible drug if needed|Strong| |\n|Stress-dose steroid at delivery: do not treat for vaginal delivery, do treat for cesarean delivery|Conditional| |\n|Breastfeeding|Encourage breastfeeding and maintain disease control with compatible medications if possible|GPS|\n|Compatible medications:|HCQ, infliximab, etanercept, adalimumab, golimumab, certolizumab, rituximab|Strong|",
            "| Prednisone                               | + (Taper to &lt;20 mg/day)                                           | + (Taper to &lt;20 mg/day)                                        | After a dose &gt;20 mg, delay breastfeeding for 4 hours            |\n| Cyclosporine, tacrolimus                 | + (Monitor blood pressure)                                        | + (Monitor blood pressure)                                     | + (Low transfer)                                               |",
            "of prednisone or nonfluorinated equivalent) during pregnancy if clinically indicated. We strongly recommend tapering higher doses of nonfluorinated glucocorticoids to <20 mg daily of prednisone, adding a pregnancy-compatible glucocorticoid-sparing agent if necessary. Although there are only minimal data regarding prolonged treatment with low-dose glucocorticoids during pregnancy, we conditionally recommend against routine administration of stress-dose glucocorticoids at the time of vaginal",
            "<p>|Recommendations for patients taking prednisone ≥2.5 mg/day for &gt;3 months|Certainty of evidence|PICO evidence report basis|Evidence Report, pp|\n|---|---|---|---|"
        ]
    }
]